Clinical optimization of pretargeted radioimmunotherapy with antibody- streptavidin conjugate and 90Y-DOTA-biotin

Journal of Nuclear Medicine

Volumn 41, Issue 1, 2000, Pages 131-140

  Breitz, Hazel B ^a   Weiden, Paul L ^b   Beaumier, Paul L ^b   Axworthy, Donald B ^b   Seiler, Chris ^b   Su, Fu Min ^b   Graves, Scott ^b   Bryan, Kyle ^b   Reno, John M ^b  

^a Poniard Pharmaceuticals Inc   (United States)

^b NONE

Author keywords

90Y dodecane tetraacetic acid biotin; Monoclonal antibody; NR LU 10; Pretargeted radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOTIN DERIVATIVE; STREPTAVIDIN; YTTRIUM 90;

ADENOCARCINOMA; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; TARGET ORGAN;

ADENOCARCINOMA; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; RADIOIMMUNOTHERAPY; TIME FACTORS; YTTRIUM RADIOISOTOPES;

EID: 0033972577     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol. 1997;15:1518-1528.
2. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med. 1994;35:1017-1022.
3. Press OW, Eary JF, Appelbaum FR, Bernstein ID. Radiolabeled antibody therapy of lymphomas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer, Vol. 4. Philadelphia, PA: Lippincott; 1994:1-13.
4. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med. 1997;38:858-870.
5. Breitz HB, Weiden PL, Vanderheyden J-L, et al. Clinical experience with Re-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J Nucl Med. 1992;33:1099-1112.
6. 90Y-labeled monoclonal antibodies as a third line of treatment in ovarian cancer: a phase 1-2 trial - problems encountered and possible solutions. Br J Cancer. 1990;10:48-51.
7. Jacobs AJ, Fer M, Su F-M, et al. A phase I trial of a rhenium-186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 1993;82:586-593.
8. 131I: comparison of the results obtained in recurrent and newly diagnosed tumors [abstract]. Cancer Res Suppl. 1995;55:595.
9. 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer. 1993;67:144-151.
10. DeNardo GL, Maddock SW, Sgouros G, Scheibe PO, DeNardo SJ. Immunoadsorption: an enhancement strategy for radioimmunotherapy. J Nucl Med. 1993;34:1020-1027.
11. Goodwin DA. Tumor pretargeting: almost the bottom line. J Nucl Med. 1995;36: 876-879.
12. Goodwin DA. Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins. Eur J Nucl Med. 1984;9:209-215.
13. Hnatowich DJ, Virzi F, Ruskowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294-1302.
14. Green NM. Avidin and streptavidin. In: Wilchek, Bayer E, eds. Methods of Enzymology: Avidin-Biotin Technology. San Diego, CA: Academic Press; 1990: 51-67.
15. Kalofonos HP, Rusckowski M, Siebecker DA, et al. Imaging of tumor in patients with In-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med. 1990;31:1791-1796.
16. 90Y radioimmunotherapy in a mouse xenograft model [abstract]. J Immunother. 1994;16:158.
17. Axworthy DB, Theodore LJ, Gustavson LM, Reno JM, inventors; NeoRx Corp., assignee. Biotinidase resistance DOTA-biotin conjugates. US patent 5,608,060. March 4, 1997.
18. Wilchek M. Lectin-mediated isolation of cell surface glycoproteins. In: Wilchek M, Bayer E, eds. Methods of Enzymology: Avidin-Biotin Technology. San Diego, CA: Academic Press, 1990:306-314.
19. Stadalnik RC, Vera DR, Woodle S, et al. Technetium-99m NGA functional hepatic imaging: preliminary clinical experience. J Nucl Med. 1985;26:1233-1242.
20. Axworthy DB, Reno JM, inventors; NeoRx Corp., assignee. Hexose derived human serum albumin clearing. US patent 5,616,690. April 1, 1997.
21. 90Y-Janus-2(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for radioimmunotherapy. Cancer Res. 1994;54:5937-5946.
22. 99mTc nofetumomab merpentan (Verluma) radioimmunoscintigraphy. Clin Nucl Med. 1997;22:615-620.
23. Breitz HB, Sullivan K, Nelp WB. Imaging lung cancer with radiolabeled antibodies. Semin Nucl Med. 1993; 23:127-132.
24. Su F-M, Hickey JJ, Taylor C, Beaumier P. In-111/Y-90 dual isotope scintillation counting method for patient samples from pretargeted cancer therapy phase I trial [abstract]. J Nucl Med. 1996;3(suppl):145P.
25. Snyder WS, Ford MR, Warner GG. Estimates of Specific Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogenous Phantom. MIRD Pamphlet No. 5. New York, NY: Society of Nuclear Medicine; 1978:5-67.
26. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York, NY: Society of Nuclear Medicine; 1988.
27. International Commission on Radiation Units and Measures. Methods of assessment of absorbed dose in clinical use of radionuclides. In: International Commission on Radiation Units and Measurements. ICRU Report 32. Washington, DC: Department of Health, Education, and Welfare; 1979.
28. Fisher DR, Badger CC, Breitz HB, et al. Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies. Antibod Immunoconjug Radiopharm. 1991;4:655-664.
29. Eve IS. A review of the physiology of the gastrointestinal tract in relation to radiation absorbed doses from radioactive materials. Health Phys. 1966;12:131-161.
30. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibod Immunoconjug Radiopharm. 1990;3:213-233.
31. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria for the Eastern Cooperative Group. Am J Clin Oncol. 1982;5:649-655.
32. Fritzberg AR. Antibody pretargeted radiotherapy: a new approach and a second chance. J Nucl Med. 1998;39:20N-22N.
33. 90Y-Janus-2(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for radioimmunotherapy. Cancer Res. 1994;54: 5937-5946.
34. Le Doussal J-M, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-1366.
35. Le Doussal J-M, Chetanneau A, Gruaz-Guyon A, et al. Bispecific monoclonal antibody mediated targeting of an indium-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med. 1993;34:1662-1671.
36. Vuillez JP, Moro D, Bodere F, et al. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-CEA/anti-DTPA antibody and the iodine-131 di-DTPA hapten: preliminary results. J Nucl Med. 1998;39P-70P.
37. Kraeber F, Bodere S, Bardet JP, et al. Phase I/II trial of two-step radioimmunotherapy in medullary thyroid cancer using bispecific anti-CEA/anti-DTPA-In antibody and I-131-labeled bivalent hapten [abstract]. J Nucl Med. 1998;39(suppl): 246P.
38. Paganelli G, Magnani P, Zito F, et al. Three-step monclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 1991;51: 5960-5966.
39. 90Y-biotin [abstract]. J Nucl Med. 1998;39(suppl):70P.
40. Breitz H, Knox S, Weiden P, et al. Pretargeted radioimmunotherapy with antibody-streptavidin and Y-90 DOTA-biotin (avicidin): results of a dose escalation study [abstract]. J. Nucl Med. 1998;39(suppl):71P.